Page 34 - Read Online

Mudra et al. J Cancer Metastasis Treat 2019;5:27 I http://dx.doi.org/10.20517/2394-4722.2019.09 Page 9 of 9

62. Lim SM, Kim HR, Lee JS, Lee KH, Lee YG, et al. Open-label, multicenter, phase ii study of ceritinib in patients with non-small-cell lung
cancer harboring ros1 rearrangement. J Clin Oncol 2017;35:2613-8.
63. Solomon B, Shaw A, Ou S, Besse B, Felip E, et al. OA 05.06 phase 2 study of lorlatinib in patients with advanced ALK+/ROS1+ non-
small-cell lung cancer. J Thorac Oncol 2017;12:S1756.
64. Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by
tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012;7:1807-14.
65. Gan GN, Weickhardt AJ, Scheier B, Doebele RC, Gaspar LE, et al. Stereotactic radiation therapy can safely and durably control sites of
extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.
Int J Radiat Oncol Biol Phys 2014;88:892-8.
66. Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, et al. Extended survival and prognostic factors for patients with ALK-
rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol 2016;34:123-9.